Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 111Recurrence 33Neoplasms, Plasma Cell 10Neoplasms 9Lymphoma, Non-Hodgkin 4Hematologic Neoplasms 3Renal Insufficiency 2Primary Myelofibrosis 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Sarcoma 1Prostatic Neoplasms 1Polycythemia Vera 1Plasmacytoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Medulloblastoma 1Malignant Plasma Cell Neoplasms 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1

Interventions

ofatumumab 10ibrutinib 6Rituximab 5acalabrutinib 4Cyclophosphamide 3spebrutinib 2pirtobrutinib 2obinutuzumab 2navitoclax 2fludarabine phosphate 2Tablets 2Lenalidomide 2KW-2478 2Chlorambucil 2Antigens, CD19 2ARQ531 2venetoclax 1tirabrutinib 1pomalidomide 1pivalyloxymethyl butyrate 1immunotoxin HA22 1idelalisib 1idecabtagene vicleucel 1fludarabine 1dinaciclib 1bempegaldesleukin 1Vincristine 1Rabeprazole 1Prednisone 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, B-Cell × pomalidomide × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡